Papillex study for abnormal cervical cells from HPV
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether Papillex, a supplement, can help clear abnormal cervical cells caused by HPV. You may be eligible if you have HPV and abnormal cell changes that haven't been treated recently.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 25 to 55
- You have HPV and abnormal cervical cells (CIN1 or worse) that were found more than 6 months ago
- You are not pregnant, breastfeeding, or planning to become pregnant, and if you can get pregnant, you agree to use birth control
- You have not had treatment for cervical cell changes in the last 5 years
- You are generally healthy and willing to keep your usual habits during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study offers a way to screen for cervical cancer using an HPV self-test. It is designed for women who may not have had a recent Pap smear and are from certain minority groups.
This study is testing a vaginal gel that might help restore the health of the cervix in women who have HPV. If you have HPV and your cervical cells are normal or only mildly abnormal, you may be able to join.
This study tests whether a vaginal gel can help early cervical cell changes (CIN1 or CIN2) go away on their own and clear the HPV virus. If you are being monitored without treatment, this gel might increase your chances of recovery.
This study tests a new vaginal medication (Dysplasix) to treat mild cervical cell changes caused by high-risk HPV. The goal is to see if this treatment can help your body clear the virus and prevent these changes from getting worse.
This trial studies 2LPAPI® to see if it helps the body clear high-risk HPV infections in the cervix. It may be an option if you have a current HPV infection with mild/early abnormal cervical findings and can complete follow-up for about a year.
This trial tests a new vaccine called PVX4 for women with HPV16-related cervical dysplasia. It aims to see if the vaccine can help clear the high-risk HPV infection and the abnormal cells on the cervix.
Hear when a new HPV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.